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Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard 
practice for the treatment of adult patients with heterozygous familial hypercholesterolemia 
(heFH), as the result of numerous studies in patients with primary hypercholesterolemia or 
heFH. These studies have shown the combination to be both effective and safe in the short 
to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective 
and safe in combination with statin therapy for children and adolescents with heFH. Effective 
statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in 
heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and 
improved life expectancy resulting predominantly from reduction in levels of low-density 
lipoprotein  cholesterol.  There  are  few  data  to  support  a  pleiotropic  action  of  ezetimibe 
with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical 
adverse effects of combination statin–ezetimibe therapy have emerged till date, although data 
are limited in children and adolescents, for whom longer-term studies are required. Recent 
data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large 
long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to 
determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever 
be performed in patients with FH.
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Introduction
Ezetimibe, the first specific inhibitor of the intestinal cholesterol uptake transporter 
Niemann–Pick C1 Like 1 (NPC1 L1) protein, was developed as an agent to lower 
plasma levels of low-density lipoprotein cholesterol (LDL-C).1
Statins are first-line drugs for treatment of elevated LDL-C levels, whereas 
ezetimibe remains one of the available second-line drugs for use in patients whose 
LDL-C levels remain above target in spite of maximally tolerated doses of statins, 
or for those who are unable to tolerate statins.2 Alternative therapy to lower LDL-C 
levels include fibrates, niacin (nicotinic acid [NA]), resins (bile acid sequesterants), 
and plant stanols and sterols.3,4
Ezetimibe has an additive and at times synergistic effect on the reduction of LDL-C 
and total cholesterol (TC) concentrations when combined with statin therapy. Thus, 
although doubling the dose of statin therapy and switching to an alternative statin 
  generally lead to a further reduction in baseline LDL-C concentrations of approximately 
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greater incremental reductions in LDL-C concentrations of 
15%–20% or more.1 The variation in response between indi-
viduals may in part be due to genetic variation.5 The intuitive 
hypothesis for improved efficacy of ezetimibe in individuals 
with high cholesterol absorption and low hepatic synthesis 
versus improved efficacy of statins in individuals with low 
absorption and high hepatic synthesis was not supported by 
the results of a recent study.6 Responsiveness to statin and 
ezetimibe were highly correlated; suggesting that factors 
downstream of the primary sites of action are major deter-
minants of response.5
In this article, we present an overview of the results of 
studies of ezetimibe in patients with primary hypercholes-
terolemia (HC) and make recommendations for the use of 
ezetimibe in patients with familial hypercholesterolemia (FH). 
This has also been the subject of two recent reviews.7,8
Familial hypercholesterolemia
FH is an autosomal dominant genetic disorder due to a 
mutation in the gene coding for the LDL receptor (LDL-R).31 
Heterozygous FH (heFH) results in functionally half of 
the normal number of hepatic LDL-Rs. As a consequence, 
decreased uptake of LDL-C from the blood occurs. This 
increases the activity of hepatic β-hydroxy-β-methylglutaryl-
CoA (HMG-CoA) reductase, the rate-limiting enzyme, in 
the pathway of cholesterol synthesis. Increased production 
of cholesterol by hepatic cells, coupled with reduced uptake 
of LDL by its hepatic receptor result in elevated plasma 
LDL-C levels 2–3 times the normal in individuals with one 
abnormal allele (heFH). Those with two abnormal alleles, 
which may be either compound heFH or true homozygous FH 
(hoFH) with identical mutant alleles, have grossly elevated 
plasma LDL-C levels 4–6 times the normal. The elevation 
in plasma LDL-C levels leads to the development of early 
and aggressive atherosclerosis and premature atherothrom-
botic vascular disease. This includes coronary artery disease 
(CAD), cerebrovascular attacks or stroke, transient ischemic 
attacks, and peripheral arterial disease.31
The incidence of heFH in the community is approximately 
1 in 300 to 1 in 500 and that of hoFH approximately 1 per 
million. In the absence of genetic screening, only 10% of 
those affected are identified before the onset of symptomatic 
disease.32 One reason for this is that the majority of affected 
individuals may not have tendon or cutaneous xanthomas, 
the presence of which would normally bring them into early 
medical management.
The key to diagnosis of FH is measurement of serum TC 
levels, often routinely performed in automated biochemistry 
laboratories. A TC level .8 mmol/L with triglyceride (TG) 
level ,2 mmol/L should alert the practitioner to the probable 
diagnosis of HeFH and the need for treatment and follow-
up as a family. A good family history taken by the primary 
practitioner may help to identify FH through a history of 
premature CVD or sudden death on one side of the family, 
usually affecting males at a younger age than females. Link-
ing this with follow-up of families of those presenting with 
early CVD should allow for cascade screening of cholesterol 
levels in near relatives and, where available, genetic screening 
with DNA analysis.
A consequence of the potential for early disease and death 
has provoked an attempt at early childhood diagnosis and 
early treatment with statins. Several community-wide and 
often nationwide programs have been instituted, including 
MEDPED (Make Early Diagnosis, Prevent early Death), 
begun in Utah by the late Professor Roger Williams.33 
Extensive screening programs are now being conducted 
in the Netherlands and Scandinavia, and less ambitious 
programs have been initiated elsewhere.34–39 Family his-
tory taking and follow-up are often difficult to accomplish 
because multiple health practitioners are involved and 
the family group is constantly changing due to births, 
deaths, and possible intermarriage. A continuous process 
is required, which needs funding by a central government   
agency.
Clinical management of FH patients is primarily with the 
use of statins (HMGCoA reductase inhibitors). In the limited 
studies which have been carried out, affected heFH persons, 
even though they may have reached presently accepted target 
levels of LDL-C, may have an additional residual risk.40 
This may be related to cumulative LDL exposure before 
beginning treatment, elevated lipoprotein(a) levels, a need 
to reduce target levels further, as yet unknown factors, or the 
so-called legacy effect caused by delay in treatment.41 It may 
also be due to a longer exposure to elevated LDL-C levels 
from birth, in contrast to hypercholesterolemic individuals 
without FH, whose raised LDL-C levels usually occur after 
puberty. The presence of other metabolic factors such as 
obesity, diabetes, hypertension, and cigarette smoking will 
also impact on residual risk.
The management of FH also focuses on the need to 
achieve general lifestyle changes involving diet modifica-
tion, abstinence from tobacco, weight reduction, and the 
undertaking of regular exercise. Identification of those at 
special risk includes patients with renal disease, albuminuria, 
depression and schizophrenia and particular ethnic groups 
including indigenous people, South Sea Islanders, and South Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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East Asians. In these cases, measurement of high-sensitivity 
C-reactive protein (hs-CRP) and/or coronary calcium 
scoring may assist with early detection of disease.42,43 Regu-
lar cardiac stress testing may also provoke more intensive 
management.
Management of FH should ideally be undertaken centrally 
in special clinics where, in addition, attention can be paid to 
the psychological effects on the family group and where a 
geneticist is available for counseling.
Drug management with statins is well accepted in the 
management of patients with heFH. These drugs have been 
in general use for over 25 years, and many relatively long-
term studies show a low incidence of side effects. In general 
use, however, there is a significant increase in the rate of 
muscle-related symptoms without evident biochemical or 
histological abnormalities.44 This raises concern for the clini-
cian especially when treating children and young adults who 
will be exposed to a lifetime of drug therapy. It is possible that 
use of other agents such as plant sterols and ezetimibe could 
allow for a reduction in statin dose and improved compliance 
with long-term therapy.
Ezetimibe in primary HC
The initial Phase II and III studies of ezetimibe were per-
formed in the early 2000s on subjects with primary HC, in 
whom secondary causes such as hypothyroidism, renal and 
hepatic disease, or diabetes had been excluded. Significant 
reductions of LDL-C with ezetimibe were observed.9–17
Subsequent studies investigated the effects of ezetimibe in 
patients with genetic HC, including FH, autosomal recessive 
hypercholesterolemia, and specific disorders of the PCSK9 
gene, all of which result in elevated levels of LDL-C.18–30 
Most of these studies in primary and genetic HC were of short 
duration (several months) and for primary HC, involved up 
to several hundred subjects per study. Studies of genetic HC 
patients have involved considerably smaller numbers.
Ezetimibe has been studied in a large number of patients 
with primary HC; some of them are likely to have had heFH, 
as levels of LDL-C were in the range typical of heFH.9–17 
However, results for heFH patients were not published 
separately.
Table 1 and Figure 1 provide the absolute and percent 
changes from baseline in mean levels of calculated plasma 
LDL-C for ezetimibe plus statin therapy in patients 
with primary HC.1 Compared with placebo, ezetimibe 
lowered LDL-C by 0.84–1.02 mmol/L (16%–19%), the 
mean reduction being 0.9 mmol/L (18%). When added to 
10 mg statin, the additional reduction in LDL-C varied 
from 0.59 to 0.85 mmol/L (13%–19%) with a mean 
reduction of 0.69 mmol/L (15.5%). When added to 20 mg 
statin, the additional reduction in LDL-C varied from 0.42 
to 0.72 mmol/L (10%–17%) with a mean reduction of 
0.63 mmol/L (13.5%). When added to 40 mg statin, the addi-
tional reduction in LDL-C varied from 0.54 to 0.80 mmol/L 
(11%–18%) with a mean reduction of 0.66 mmol/L (14%). 
When added to 80 mg statin, the additional reduction in 
LDL-C varied from 0.36 to 0.53 mmol/L (7%–13%) with a 
mean reduction of 0.45 mmol/L (10%).
The change in LDL-C levels, therefore, diminished both 
in absolute terms and as a percentage of baseline when 
ezetimibe was added to increasing doses of statins. The 
greatest changes were observed when ezetimibe alone was 
compared with placebo. These data are relevant to clinical 
expectations of the response to ezetimibe monotherapy 
Table 1 Primary hypercholesterolemia: change from baseline in calculated plasma LDL-C for ezetimibe alone and combined with 
statins or placebo1
AV SV PV LV
Placebo 0.20 (+4%) −0.08 (−1%) −0.03 (−1%) 0.00 (0%)
e −0.92 (−20%) −0.92 (−19%) −0.91 (−20%) −0.86 (−19%)
10 mg S −1.76 (−37%) −1.25 (−27%) −0.96 (−21%) −0.94 (−20%)
e + 10 mg S −2.46 (−53%) −2.10 (−46%) −1.55 (−34%) −1.56 (−34%)
20 mg S −1.91 (−42%) −1.74 (−36%) −1.10 (−23%) −1.18 (−26%)
e + 20 mg S −2.59 (−54%) −2.16 (−46%) −1.82 (−40%) −1.87 (−41%)
40 mg S −2.09 (−45%) −1.75 (−38%) −1.43 (−31%) −1.44 (−30%)
e + 40 mg S −2.69 (−56%) −2.55 (−56%) −1.97 (−42%) −2.15 (−46%)
80 mg S −2.57 (−54%) −2.11 (−45%)  – –
e + 80 mg S −2.93 (−61%) −2.64 (−58%)  – –
Pooled data: All S  −2.08 (−44%) −1.71 (−36%) −1.16 (−25%) −1.19 (−25%)
Pooled data: All e + S −2.67 (−56%) −2.36 (−51%) −1.78 (−39%) −1.86 (−40%)
Note: Values represent mean absolute change (in mmol/L) from baseline, and values in parenthesis represent mean percent change from baseline.
Abbreviations: AV, atorvastatin; SV, simvastatin; PV, pravastatin; LV, lovastatin; e, ezetimibe; S, statin.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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compared with statin–ezetimibe combination therapy at 
various doses of statins.
Table 2 shows the results for a pooled analysis of all 
ezetimibe plus statin doses for changes from baseline in 
TC, apolipoprotein B-100 (apoB), TG, and high-density 
lipoprotein cholesterol (HDL-C) levels.1
Table 3 shows the response to addition of ezetimibe 
to on-going statin therapy in patients with primary HC. 
Percentages of patients receiving each statin are as follows: 
40% atorvastatin, 31% simvastatin, and 29% others 
(pravastatin, fluvastatin, cerivastatin, and lovastatin).1
In summary, the above studies in patients with primary 
HC (predominantly non-FH) showed that ezetimibe mono-
therapy or ezetimibe combined with a statin significantly 
reduces TC, LDL-C, apoB, and TG and increases HDL-C 
levels compared with placebo. Reduction in LDL-C is con-
sistent across age, sex, race, and baseline LDL-C. In addition, 
ezetimibe has no effect on the plasma concentrations of the 
fat-soluble vitamins A, D, and E and on the prothrombin 
time, and it does not impair adrenocortical steroid hormone 
production.1
The UK National Institute for Health and Clinical 
Excellence (NICE) guidance recently reviewed the results 
of several randomized controlled clinical trials with 
ezetimibe in patients with primary HC, with and without 
prior CVD.7 Average baseline LDL-C concentrations ranged 
from 3.4 to 6.5 mmol/L. Thirteen trials met the criteria of 
their review, and all were considered to be well designed and 
conducted. They varied in duration from 12 to 48 weeks. 
No studies reported health-related quality of life or clinical 
end-points such as CVD morbidity and mortality. Levels 
of TC, LDL-C, HDL-C, and TG were used as indicators of 
outcomes. No information was available on pretrial treatment 
history.
To represent the population of people with HC that 
is not appropriately controlled with statin therapy, six 
12-week, fixed-dose randomized controlled trials (RCTs, 
n = 3,610) were identified that compared ezetimibe plus 
statin therapy with statin therapy alone.7 The NICE 
Assessment Group   carried out a meta-analysis on the 
RCTs. Ezetimibe plus statin therapy was associated with 
an additional mean reduction in TC and LDL-C levels of 
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10.4% (95% confidence interval [CI]: 11.1–9.6) and 13.9% 
(95% CI: 14.9–13.0), respectively, for prestatin treatment 
concentrations compared with statin therapy alone. This 
equated to a 22.4% reduction achieved by the combina-
tion of ezetimibe plus statin compared with an on-statin 
baseline LDL-C level.
Four extension studies (n = 1,800) compared ezetimibe 
plus statin therapy with a titrated statin dose.7 One study 
included an heFH subgroup; in the ezetimibe plus statin 
arm, 17% reached the LDL-C target (2.6 mmol/L or less) 
compared with 4% in the statin monotherapy arm.
The NICE Assessment Group carried out an additional 
meta-analysis of shorter-term studies (less than 12 weeks in 
duration) comparing ezetimibe coadministered with statin 
therapy vs statin therapy alone.7 The results showed that 
the addition of ezetimibe to statin therapy reduced LDL-C 
concentrations by 23.2% more than statin therapy alone.
Seven RCTs (n = 2,577) comparing ezetimibe monother-
apy with placebo represented the population in which statin 
therapy is considered inappropriate or is not tolerated.7 All 
were 12-week studies and were included in a meta-analysis 
performed by the NICE Assessment Group. Ezetimibe mono-
therapy was associated with a statistically significant mean 
reduction in TC concentrations (13.4%; 95% CI: 14.2–12.6) 
and LDL-C concentrations (18.6%; 95% CI: 19.7–17.4) 
compared with placebo.
Four studies demonstrated LDL-C-lowering effects of 
ezetimibe treatment across subgroups, including different 
ethnic groups and people with or without conditions such 
as CVD, diabetes, and heFH.7 None of the subgroup 
comparisons showed statistically significant differences 
between subgroups. All other trials reported that the effect of 
ezetimibe therapy on LDL-C levels was generally consistent 
across all subgroups. There was no evidence to suggest a 
difference in the effectiveness of ezetimibe in any subgroup, 
including people with heFH or diabetes, or people with or 
without a history of CVD.7
The NICE guidance meta-analysis showed that ezetimibe 
plus statin therapy reduces LDL-C levels by an additional 
13.9% compared with statin therapy alone.7 This absolute 
change was approximately 22% when calculated as a 
proportion of the poststatin LDL-C levels.
The clinical effectiveness of ezetimibe, based on its mode 
of action, is unlikely to differ markedly between different ethnic 
groups; therefore, separate recommendations for different 
ethnic groups were not made in the NICE guidelines.7
Table 2 Pooled analysis of absolute and percent change from baseline in total cholesterol (TC), apolipoprotein B (apoB), triglyceride 
(TG), and high-density lipoprotein cholesterol (HDL-C) for ezetimibe therapy in combination with various statin doses.1 Data from   
four multicenter double-blind randomized controlled trials of 12-week duration in patients with hyperlipidemia1
TC ApoB TG HDL-C N
e + AV −2.86 (−41%) −0.78 (−45%) −0.55 (−33%) 0.09 (+7%) 255
AV alone −2.24 (−32%) −0.61 (−36%) −0.40 (−24%) 0.05 (+4%) 248
e + SV −2.49 (−37%) −0.69 (−41%) −0.53 (−29%) 0.11 (+9%) 274
SV alone −1.78 (−26%) −0.51 (−30%) −0.32 (−20%) 0.09 (+7%) 263
e + PV −1.86 (−27%) −0.51 (−30%) −0.36 (−21%) 0.10 (+8%) 204
PV alone −1.17 (−17%) −0.35 (−20%) −0.26 (−14%) 0.08 (+7%) 205
e + LV −1.96 (−29%) −0.57 (−33%) −0.44 (−25%) 0.10 (+9%) 192
LV alone −1.25 (−18%) −0.36 (−21%) 0.21 (−12%) 0.04 (+4%) 220
Note: Values represent mean absolute change from baseline, mmol/L for lipid levels and mg/dL for apoB levels, and values in parenthesis represent mean percent change 
from baseline.
Abbreviations: e, ezetimibe; AV, atorvastatin; SV, simvastatin; PV, pravastatin; LV, lovastatin.
Table 3 Response to addition of ezetimibe to on-going statin therapy in patients with primary hypercholesterolemia (HC): absolute 
and percent changes from baseline.1 Data from 8-week trials of patients with primary HC, known coronary heart disease of multiple 
cardiovascular risk factors on statin monotherapy who had not achieved National Cholesterol education Program Adult Treatment 
Panel (NCeP-ATP iii) goals1
N TC LDL-C ApoB TG HDL-C
S + PV 390 −0.16 (−2%) −0.16 (−4%) 0.05 (−3%) 0.05 (−3%) +0.00 (+1%)
S + e 379 −0.99 (−17%) −0.92 (−25%) −0.27 (−19%) −0.19 (−14%) +0.03 (+3%)
e − PV −0.83 (−15%) −0.76 (−21%) −0.22 (−16%) −0.14 (−11%) +0.03 (+2%)
Note: Values represent mean absolute change (in mmol/L) from baseline, and values in parenthesis represent mean percent change from baseline.
Abbreviations: TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoB, apolipoprotein B; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; 
S, statin; PV, pravastatin; e, ezetimibe.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Ezetimibe in FH
The initial, multicenter, double-blind, 14-week study of 
621 hypercholesterolemia patients included approximately 
60% of patients with heFH.1 Those receiving atorvastatin 
10 mg daily with an LDL-C .3.36 mmol/L were random-
ized to receive atorvastatin 20 mg or ezetimibe 10 mg 
added to atorvastatin 10 mg therapy. The atorvastatin 
dose could be titrated up to 80 mg in the atorvastatin 
arm and up to 40 mg in the ezetimibe plus atorvastatin 
coadministration arm, based on patients not attaining 
LDL-C goal (,2.59 mmol/L). The mean baseline LDL-C 
was 4.84 mmol/L. At study end, there was a significant 
difference in attainment of LDL-C goal between patients 
in the ezetimibe coadministration arm (22%) and patients 
on atorvastatin monotherapy (7%). At week 4, there was 
a significant difference in LDL-C reductions between 
coadministration patients (24%; ezetimibe plus atorvas-
tatin 10 mg) and monotherapy patients (9%; atorvastatin 
20 mg). In the subgroup of patients with heFH, similar 
results for LDL-C goal attainment and LDL-C reductions 
were achieved.
Several subsequent studies confirmed these results in 
heFH patients. The NICE Assessment Group carried out an 
additional subgroup analysis of the effect of ezetimibe ther-
apy in people with or without heFH. The greater reductions 
in LDL and TC concentrations in the heFH group were not 
found to be statistically significant.7
Ezetimibe in hoFH
The initial study was a double-blind, randomized, 12-week 
study of 50 patients, with a clinical and/or genotypic 
diagnosis of hoFH, with or without concomitant LDL aphere-
sis, who were already receiving atorvastatin or simvastatin 
(40 mg).1 Patients were randomized to 1 of 3 treatment 
groups, atorvastatin or simvastatin (80 mg), ezetimibe 
10 mg administered with atorvastatin or simvastatin (40 mg), 
or ezetimibe 10 mg administered with atorvastatin or 
simvastatin (80 mg). Results are shown in Table 4.1 Ezetimibe 
administered with atorvastatin (40 or 80 mg) or simvastatin 
(40 or 80 mg) significantly reduced LDL-C compared with 
increasing the dose of simvastatin or atorvastatin mono-
therapy from 40 to 80 mg.
Several subsequent studies have confirmed the efficacy 
of ezetimibe in hoFH.45–52
Ezetimibe in children with FH
A small number of short-term studies have investigated the 
efficacy and tolerability of ezetimibe in children with FH.53–56 
In general, ezetimibe was well tolerated with similar results 
to those observed in adult subjects with FH. No long-term 
data are available.
Ezetimibe in addition to other 
therapies in FH
Isolated reports have been published on the use of ezetimibe 
in addition to LDL-apheresis in patients with resistant FH.57 
Further LDL-C reductions of 11%–25% have been observed 
with no evident adverse effects.
Ezetimibe in human 
immunodeficiency virus infection
Many of the protease inhibitors used in the treatment of 
human immunodeficiency virus (HIV) infection will induce 
mixed forms of dyslipidemias, and in FH, patients have 
the potential for further deterioration. Studies in children, 
however, show the changes were of the same degree as 
non-FH patients.58
Antiviral drugs and HIV protease inhibitors have an 
increased risk of myopathy when used with statins, and so 
they should be used with care. Pravastatin is least likely to 
be a problem, as it is not substantially metabolized by cyto-
chrome P450 in the liver. Simvastatin should be avoided.59 
Rosuvastatin has some promise, as it is excreted 90% intact in 
the feces and so it would not have a great effect on the P450 
enzymes to induce dangerous levels of the drug. However, 
small trials have shown increases in serum rosuvastatin 
varying from 61% to 76%, depending on the antiviral drug 
used.60 Although no clinical problems were encountered in 
these small short-term trials, there is clearly need for care. 
When any statin is used patients must be alerted to watch for 
muscle symptoms such as muscle pain, stiffness, weakness, 
or cramps.
Ezetimibe therapy may play an important role in reducing 
the dose of statin required, thus reducing adverse side effects. 
Hence, it may be considered for use when target levels of 
Table 4 Mean LDL-C response to ezetimibe in patients with 
homozygous familial hypercholesterolemia1
Treatment (daily dose) N LDL-C (mmol/L)
Changea % Changeb
AV or SV (80 mg) 17 −0.51 −7%
e + AV or SV (40, 80 mg) 33 −1.76 −21%
e + AV or SV (80 mg) 17 −2.00 −27%
Notes: aMean absolute change from baseline (mmol/L). bMean percent change from 
baseline.
Abbreviations: AV, atorvastatin; SV, simvastatin; e, ezetimibe.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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LDL-C have not been reached and side effects or risk of side 
effects are present.
The studies that have been conducted using ezetimibe in 
conjunction with pravastatin in the presence of the protease 
inhibitors are of limited usefulness because of the small number 
of patients. These have shown only modest decrease in LDL-C 
levels (22%) and small increase in HDL-C levels but with 
no new or enhanced side effects noted. Ezetimibe, therefore, 
seems to be a safe drug when used in this context. A Canadian 
study is presently underway in which rosuvastatin 10 mg plus 
ezetimibe 10 mg is compared with rosuvastatin 20 mg in HIV 
patients being treated with protease inhibitors.61
Antiatherosclerotic and pleiotropic 
effects of ezetimibe
Animal experiments have shown antiatherosclerotic effects 
with ezetimibe therapy, in part possibly mediated by nonlipid 
(pleiotropic) mechanisms, the significance of which is 
controversial.62–68 In apoE knockout (ko) mice, aortic lesion 
formation was significantly reduced by ezetimibe therapy.62 
Ezetimibe treatment resulted in a significant reduction in 
plaque size and macrophage and fibronectin extra domain-B 
immunoreactivity in brachiocephalic lesions, indicating 
plaque regression.66 Similar results were also shown with 
high-intensity (7 T) magnetic resonance imaging.63
In rabbits, femoral atherosclerosis was induced by a 
combination of endothelial desiccation and atherogenic diet.60 
Ezetimibe treatment reduced the intima/media ratio by 13%, 
simvastatin therapy by 27%, and ezetimibe plus simvastatin 
therapy by 28% compared with control rabbits. Ezetimibe 
decreased macrophage content and monocyte chemoattrac-
tant protein 1 (MCP-1) expression in atherosclerotic lesions 
and reduced the increased activity of nuclear factor-κB 
in peripheral blood leucocytes and plasma CRP levels. In 
THP-1 cells, ezetimibe decreased MCP-1-induced monocyte 
migration. The combination of ezetimibe with simvastatin 
was associated with a more significant reduction in plaque 
monocyte/macrophage content and some proinflammatory 
markers than observed with either drug alone.64
In another study, apoE ko and apoE/endothelial nitric 
oxide synthase (eNOS) double ko (dko) mice received a high-
fat diet with or without 0.05% ezetimibe.61 Ezetimibe therapy 
significantly reduced plasma cholesterol   concentrations 
and atherogenic lipoproteins in both genotypes to a similar 
extent. Moreover, the drug reduced vascular inflammation, 
as it significantly reduced vascular cell adhesion   molecule 1 
expression and vascular CD14 expression, a marker for mono-
nuclear cell infiltration, in both genotypes. Neither NOS 
protein expression nor vascular reactivity of aortic rings was 
changed in apoE ko mice following ezetimibe treatment. Sig-
nificant lesion reduction was seen in ezetimibe-treated male 
and female apoE ko and apoE/eNOS dko animals (P # 0.05). 
The drug-mediated additional atheroprotection in male 
apoE ko mice compared with male eNOS dko mice suggests 
that lipid lowering does provide additional eNOS-dependent 
atheroprotection in this experimental group.65
Yorkshire pigs treated with streptozotocin to induce 
diabetes mellitus (DM) were treated with either atorvastatin 
or ezetimibe and evaluated for the number of bone marrow 
and circulating endothelial progenitor cells (EPCs) and for 
femoral artery endothelial function.66 There was no effect 
of either medication on cholesterol level. One month after 
induction of DM prior to administration of drugs, the number 
of bone marrow and circulating EPCs significantly decreased 
(P , 0.0001) compared with baseline. Three months after 
DM induction, the mean proportion of circulating EPCs 
significantly increased in the atorvastatin group, but not in 
the control or ezetimibe groups. The control group showed 
progressive reduction in percentage of flow-mediated 
vasodilatation (no dilatation at 3 months), whereas the 
atorvastatin group and ezetimibe group exhibited 6% and 
4% vasodilatation, respectively.66
One study investigated endothelial function in 20 patients 
with heart failure treated with either simvastatin or simvas-
tatin plus ezetimibe.69 Simvastatin and ezetimibe treatment 
reduced LDL-C to a similar extent (15.6% vs 15.4%; P = not 
significant [NS]), whereas changes in mevalonate, the 
product of HMGCoA reductase, differed between groups 
(∆ mevalonate–simvastatin, −1.04 ± 0.62 vs ∆ mevalonate-
ezetimibe, 1.79 ± 0.94 ng/mL; P , 0.05 between groups). 
Flow-mediated dilatation (FMD) was markedly improved 
after simvastatin (10.5 ± 0.6% vs 5.1 ± 0.7%; P , 0.01) but 
not after ezetimibe treatment (5.6 ± 0.5% vs 5.8 ± 0.6%; 
P = NS). The ∆ FMD before and after intra-arterial infusion 
of vitamin C to determine the portion of FMD inhibited 
by radicals was substantially reduced after simvastatin but 
not after ezetimibe treatment. Extracellular superoxide 
dismutase activity was increased by .100% (P , 0.05) 
after simvastatin but not ezetimibe treatment. Simvastatin 
treatment increased the number of functionally active EPCs, 
whereas ezetimibe had no effect.69
Similar results were observed in a study of forearm 
blood flow (FBF) responses to acetylcholine (ACH) and 
sodium nitroprusside, measured by venous occlusion 
plethysmography, in four prospectively defined groups 
of patients with stable CAD before and after 4 weeks of Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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lipid-lowering therapy.70 Ezetimibe 10 mg/d monotherapy 
(N = 15) was compared with long-term administration of 
simvastatin 20 mg/d plus add-on ezetimibe (N = 15). After 4 
weeks of therapy, LDL-C levels were significantly reduced in 
both groups. Neither ezetimibe monotherapy nor ezetimibe 
combined with 20 mg simvastatin was associated with an 
increase in ACH-mediated FBF responses after 4 weeks. It 
was concluded that both statins and ezetimibe effectively 
lower LDL levels within 4 weeks of therapy, but only statin 
therapy is associated with improved endothelial vasodilator   
function.70
Another study investigated synthesis of isoprenoids, 
which are important for mediating signalling through the 
Rho-associated coiled-coil containing protein kinase (ROCK) 
pathway.71 Increased ROCK activity has been implicated in 
endothelial dysfunction and vascular inflammation, and statins 
reduce isoprenoid synthesis and ROCK activity. Dyslipidemic 
subjects (N = 60) without cardiovascular disease (CVD) were 
randomized to treatment with simvastatin 40 mg/d, simvas-
tatin/ezetimibe 10/10 mg/d, or placebo tablets for 28 days 
(n = 20 in each arm). Compared with the placebo group, both 
treatment regimens decreased LDL-C by 38% and CRP by 
38%–40% after 28 days (P , 0.01 for both compared with 
placebo). Although the LDL-C and CRP reductions were 
comparable with either lipid-lowering regimen, only sim-
vastatin 40 mg reduced ROCK activity and improved FMD 
(P , 0.01 for both compared with baseline). Reduction in 
ROCK activity with simvastatin 40 mg remained significant 
even after controlling for changes in LDL-C (P = 0.01) and 
correlated with improvement in FMD (R2 = –0.78, P , 0.01). 
No correlation was found between changes in FMD and 
changes in LDL-C or CRP.71
The effects of ezetimibe on hs-CRP were reported in a 
meta-analysis of 13 randomized placebo-controlled trials with 
ezetimibe and statin therapy.72 Six were monotherapy trials of 
12-week duration (N = 1,372), and 7 involved 6–8 weeks of 
add-on ezetimibe to stable statin therapy (N = 3,899). A 6% 
additional reduction was observed comparing ezetimibe with 
placebo (P = 0.094). A 10.4% reduction was observed for 
ezetimibe and statin therapy, which was significantly greater 
than placebo (P , 0.001). Weak significant correlation was 
observed between baseline hs-CRP and LDL-C levels only 
in the ezetimibe add-on groups. It was concluded that the 
lowering of hs-CRP with statin therapy was enhanced by 
ezetimibe to a small degree, the clinical significance of which 
is uncertain.72
A review of the published literature characterizing the 
impact of ezetimibe-containing lipid-lowering regimens on 
endothelial function and other markers of cardiovascular 
risk, and the potential relevance of these effects on the 
clinical benefit of ezetimibe, concluded that ezetimibe, 
either as monotherapy or in combination with a statin, 
exerts minimal beneficial effects on endothelial function 
and other ancillary measures of CVD risk beyond those 
conferred by its cholesterol-lowering effects.73 Recent 
studies in patients with CAD, heart failure, and hypercho-
lesterolemia demonstrated that treatment with ezetimibe 
for 4–12 weeks elicits no improvement of endothelial 
function or other measures of CVD risk. In contrast, other 
studies have reported that ezetimibe improves endothelial 
function in certain patient populations, including those 
with rheumatoid arthritis, CAD with type 2 diabetes, and 
metabolic syndrome.73 However, the statin monotherapy 
comparator groups in these studies that yielded equivalent 
reductions in cholesterol were superior, or at least equivalent 
to, ezetimibe-containing regimens in the improvement of 
these ancillary end-points. It was suggested that studies with 
larger sample sizes and follow-up beyond 12 weeks were 
necessary to further define the impact of ezetimibe on the 
processes integral to the pathogenesis and progression of   
CVD.73
Outcomes of ezetimibe therapy
LDL-C level as a surrogate outcome
The NICE guidance on ezetimibe for the treatment of 
primary HC considered the published evidence on the 
correlation between changes in lipid concentrations to 
reductions in CVD events, in which lowering LDL-C 
levels is associated with CVD outcome benefits indepen-
dent of the treatment used.7 It was concluded there is suf-
ficient evidence to link reductions in LDL-C levels from 
ezetimibe therapy with future reductions in CVD events. 
This has been the approach of regulatory bodies around the 
world, which have not required demonstration of benefit in 
clinical CVD outcomes in order for ezetimibe to be regis-
tered, although the validity of this approach is now being   
questioned.7
Carotid intima-media thickness  
as a surrogate outcome
Limited studies of surrogate imaging outcomes for CVD 
have been performed with ezetimibe. The three trials 
(SANDS, ENHANCE, and ARBITER 6-HALTS) have 
investigated the effects of ezetimibe on carotid intima-
media thickness (CIMT), a validated surrogate marker for   
CVD.74Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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SANDS
The Stop Atherosclerosis in Native Diabetics Study 
(SANDS) investigated the effects of standard vs aggressive 
management of risk factors in 499 North American Indian 
men and women aged .40 with type 2 diabetes, hyperten-
sion, and dyslipidemia.75,76 Multiple risk factors (blood pres-
sure [BP], glucose, and lipids) were targeted with stepped 
treatment algorithms. Aggressive therapy lowered LDL-C 
and systolic BP (SBP) levels to 1.7 mmol/L and 117 mm Hg 
compared with 2.7 mmol/L and 129 mm Hg, respectively, 
in the standard group. Ezetimibe was used more often in the 
aggressive treatment group in which regression of CIMT 
and greater reduction in left ventricular mass index were 
observed (see Table 5). However, ezetimibe use was not 
randomized. Baseline levels of CIMT in SANDS trial were 
increased (mean, 0.9 mm).
eNHANCe
The Effect of Combination Ezetimibe and High-Dose 
  Simvastatin vs Simvastatin Alone on the Atherosclerotic 
Process in Patients with Heterozygous Familial Hypercho-
lesterolemia (ENHANCE) trial investigated the effects of 
therapy on CIMT in patients with heFH.40,77–86
ENHANCE was an imaging study designed to examine 
change in CIMT in a select population of FH patients, with a 
mean LDL-C baseline 8.2 mmol/L (317 mg/dL) after a 6-week 
washout, treated with either maximum dose statin (simvastatin 
80 mg/d) compared with ezetimibe 10 mg/d plus simvastatin 
80 mg/d.40 There was no measurable CIMT impact by the 
addition of ezetimibe to simvastatin 80 mg/d.
Patients were followed over a 24-month period with 
measures of CIMT taken at 6-month intervals. The study 
found similar rates of CIMT progression in the simvastatin 
and the simvastatin–ezetimibe groups. Baseline mean CIMT 
levels were within the normal range (,0.7 mm).
Although no significant CIMT regression was seen in 
the selected population (N = 720), the majority (over 80%) 
had previously been treated for FH with statin therapy, and 
no adverse outcomes were seen. Results for the remaining 
20% of statin-naïve patients were not published. Importantly, 
there was no control group treated with ezetimibe, which 
could be compared with the statin–ezetimibe group in order 
to determine the effects of ezetimibe therapy alone on CIMT 
progression.
The ENHANCE study results provided little insight to the 
benefit or nonbenefit of statin and ezetimibe combinations 
in this patient group because of problematic study design, 
especially with regard to patient selection; there were no 
  prewashout criteria for either CIMT or LDL-C levels. This 
was a high-risk population that did not attain treatment 
  targets, and furthermore, the prewashout lipid values and 
prestudy lipid-lowering treatments of subjects were not 
included in the data collected for the ENHANCE study.
Although this trial showed no benefit in reducing CIMT 
by the combination of simvastatin and ezetimibe, it did 
show the expected lowering of LDL-C and apoB levels. The 
ENHANCE trial demonstrated a 16% greater   reduction 
in LDL-C in the combination group compared with the 
simvastatin-alone group over the 24-month period, as well 
as 18% greater reduction in hs-CRP.
The earlier Effects of Atorvastatin and Simvastatin on 
Atherosclerosis Progression (ASAP) study compared the 
effects of statin therapy on CIMT in patients with FH.39 
There was significantly greater CIMT regression with 
atorvastatin 80 mg/d compared with simvastatin 80 mg/d. 
Inclusion   criteria for ASAP included LDL-C . 4.5 mmol/L 
(.173 mg/dL) and CIMT . 0.7 mm. In ENHANCE, patients 
were required to have LDL-C . 5.4 mmol/L (210 mg/dL) 
after washout of prior therapy, without minimal require-
ment for CIMT levels. Baseline CIMT levels of ASAP and 
Table 5 Results of The Stop Atherosclerosis in Native Diabetics Study (SANDS)75
End-point Aggressive therapya Standard therapyb P value
Baseline CiMT (mm) 0.81 [0.78, 0.83] 0.80 [0.78, 0.82] NS
Mean CiMT change at 36 mo (mm) −0.012 [−0.03, 0.003] +0.038 [0.02, 0.06] ,0.001
Left ventricular mass index (g/mm2.7) −2.4 [−3.2, −1.6] −1.2 [−1.9, −0.4] 0.03
Carotid artery area (mm2) −0.02 [−0.33, +0.30] +1.05 [0.73, 1.38] ,0.001
Adverse events (%)c 38.5 [32, 45] 26.7 [21, 32] 0.005
Serious adverse eventscd 29.4 [24, 35] 22.3 [17, 28] NS
Notes:  aAggressive therapy was to achieve primary targets of the following: low-density lipoprotein cholesterol (LDL-C) # 70 mg/dL (1.8 mmol/L), nonhigh-density 
lipoprotein cholesterol (non-HDL-C) , 100 mg/dL (2.6 mmol/L), and systolic blood pressure (SBP) # 115 mm Hg. Figures in brackets refer to 95% confidence intervals. 
bStandard therapy was to achieve primary targets of the following: LDL-C # 100 mg/dL (2.6 mmol/L), non-HDL-C # 130 mg/dL (3.4 mmol/L), and SB # 130 mm Hg. cThe 
nature of these events was not described in the original publication other than excluding cardiovascular events. dNo serious adverse events were related to lipid drugs; four 
events were related to BP drugs in the aggressive group and 1 in the standard group (P = 0.18).
Abbreviations: CIMT, carotid intima-media thickness; NS, not significant.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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ENHANCE were ∼0.9 and ∼0.7 mm, respectively. This may 
explain to a large extent the different outcomes of ASAP 
and ENHANCE because changes in response to therapy are 
correlated with baseline values of LDL-C and CIMT (greater 
changes in CIMT occur with higher baseline values).39 The 
failure in ENHANCE to reduce CIMT in FH patients with 
the same mean age and same dose of the same drug as ASAP 
may therefore be due to higher baseline CIMT in ASAP. In 
both ASAP and ENHANCE studies the biggest predictor of 
change in CIMT in response to statin therapy was baseline 
CIMT (r = 0.53, ENHANCE; r = 041, ASAP).
Since the 1990s, the authors of these two studies 
have identified most FH patients in the Netherlands; the 
percentage of patients treated with statins increased from 
39% to 91% in 2001.34 In the same year, the ASAP pub-
lication stated that adult FH patients should be treated 
to decrease LDL-C by a minimum of 45%.83 Patients in 
ENHANCE were, therefore, likely to have been aggres-
sively treated with statins well before beginning the 
enrolment, leading to stabilization of their carotid disease 
and normalization of CIMT levels. It is likely that these 
vessels were less capable of further regression as a result 
of significant LDL-C lowering, after they attained rela-
tively normal morphology. Furthermore, the propensity 
for progression may also have been altered, although its 
effect on CIMT outcomes in ENHANCE are difficult to   
determine.
ARBiTeR 6-HALTS
The Arterial Biology for the Investigation of the Treatment 
Effects of Reducing Cholesterol-6-HDL and LDL Strategies 
in Atherosclerosis (ARBITER 6-HALTS) trial compared 
the effects on CIMT progression of extended-release NA, 
titrated to a daily dose of 2 g with that of 10 mg daily dose 
of ezetimibe in patients who were at target LDL-C levels 
(,2.6 mmol/L) as a result of statin therapy.87 NA cotherapy 
resulted in significant CIMT regression, whereas ezetimibe 
cotherapy had no significant effect on CIMT. Retrospective 
analysis showed a paradoxical significant inverse relationship 
between LDL-C and CIMT in patients treated with ezetimibe 
(R = −0.31, P , 0.001), and there was no significant asso-
ciation between LDL-C and CIMT in the group treated with 
NA (R = −0.01, P = 0.92).83 These unexpected results may be 
related to the low LDL-C levels already achieved as a result 
of concomitant statin therapy. In a subsequent publication, 
the authors of the ARBITER 6-HALTS trial showed that 
increased exposure to ezetimibe was associated with CIMT 
progression.88
The possible adverse effects of ezetimibe were explained 
on the basis of mild inhibition of acyl   coenzyme A:   cholesterol 
acyltransferase, which may worsen atherosclerosis.87 
Ezetimibe has also been shown to inhibit SRB1, the 
hepatic HDL receptor, a mechanism that may inhibit 
reverse   cholesterol transport and promote atherogenesis.87 
Recently, ezetimibe was shown to increase the propor-
tion of small, dense LDL-particles (sdLDL) in normal 
subjects after 2 weeks of therapy.89 Ezetimibe significantly 
increased the sdLDL subfractions LDL-IVA and LDL-IVB 
(+14.2% and +16.7%, respectively), whereas simvastatin 
significantly decreased the LDL-IVB subfraction (−16.7%). 
With simvastatin–ezetimibe combination therapy, the LDL-
IVB   subfraction was increased (+14.3%, NS). Each of the 
three treatments decreased the large LDL-I subfraction, 
especially ezetimibe (ezetimibe –13.9%, P , 0.0001; com-
bination therapy −7.3%, P = 0.0743; simvastatin −4.6%, 
P , 0.0001). The significance of this finding remains unclear 
for several reasons. Firstly, other studies have shown contra-
dictory results, and LDL functional assays are required to 
assess whether or not ezetimibe-induced sdLDL particles 
behave differently from normal LDL particles with regard to 
propensity for oxidation and uptake by macrophages, among 
other potential effects.90
In the past, almost all studies of CIMT have indicated a 
close correlation between CIMT, atherosclerosis severity, and 
CVD risk, leading to the concept of CIMT as a valid surrogate 
marker.74 Furthermore, ezetimibe therapy has shown to result 
in atherosclerosis regression in experimental models.62–66 
Further prospective studies are, therefore, required to provide 
more information on this potential adverse effect of ezetimibe 
therapy in relation to CIMT, atherosclerosis progression and 
CVD events.86 It is now appropriate to discuss long-term 
clinical outcomes studies with ezetimibe.
Clinical outcomes – non-FH patients
SeAS
To date, no long-term studies of CVD outcomes have been 
published with the exception of the Simvastatin and Ezetimibe 
in Aortic Stenosis (SEAS) trial.91 The SEAS trial was designed 
to investigate the efficacy of ezetimibe and simvastatin on the 
progression of aortic valve disease. Compared with placebo, 
LDL-C was reduced by 61% (2.0 mmol/L). There was no dif-
ference in the primary end-point (a combination of aortic valve 
replacement (AVR), CV death, nonfatal myocardial infarction, 
congestive heart failure from aortic stenosis progression, 
coronary revascularization, hospitalized unstable angina, and 
nonhemorrhagic stroke). Compared with placebo, ischemic Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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CVD events were reduced by 4.4% from 20.1% to 15.7% in 
the simvastatin/ezetimibe group (P = 0.02). The event reduc-
tion was largely driven by reduction in coronary artery bypass 
graft (CABG) surgery procedures that were performed at the 
same time as AVR.91 The results of SEAS suggest either a 
more favourable symptomatic outcome (less angina requiring 
CABG) or a reduction in coronary atherosclerosis severity in 
the ezetimibe and simvastatin group, for which less frequent 
CABG surgery was required.92 No data on these end-points 
have been published, however.
iMPROVe-iT
The Improved Reduction of Outcomes: Vytorin Efficacy 
International Trial (IMPROVE-IT), a large-scale clinical 
end-point trial is currently being conducted. This trial com-
pares the effects of simvastatin vs simvastatin plus ezetimibe 
  (Vytorin) on CVD end-points in approximately 18,000 
patients with high cardiovascular risk.93 IMPROVE-IT is 
expected to be completed in June 2013.
Clinical outcomes – FH patients
To the authors’ knowledge, no long-term CVD outcome 
trials in patients with genetic HC treated with ezetimibe are 
being conducted or are planned. This may reflect the number 
of patients required for such a trial because it would require 
a comparator study in which both arms were treated with 
  LDL-lowering therapy, as it would be unethical to use a 
placebo arm for FH patients.
At the time of writing, several short-term trials are either 
currently recruiting FH patients for ezetimibe therapy or 
have been completed. They include studies of chylomicron 
metabolism and effects of therapy in children, adolescents, 
Japanese, and Filipinos.94
Safety and adverse effects
There are limited long-term data on adverse events   relative 
to the use of statins, but no significant adverse events of 
ezetimibe have emerged outside of the trials other than 
isolated reports of ezetimibe-associated musculoskeletal 
symptoms that are clinically similar to those with statin 
therapy, the mechanisms of which are speculative.95–97 In 
addition, there has been no evidence of any existing increase 
in all-cause mortality, or of specific mortality, as a result of 
treatment with ezetimibe.1
An increased incidence of cancer was reported in the 
SEAS trial in the group receiving ezetimibe compared with 
placebo.91 These results prompted interim analysis of two 
other long-term trials being conducted at the time – the 
IMPROVE-IT and Study of Heart and Renal Protection 
(SHARP) trials.98 No increase in cancer incidence was 
observed in these trials, and it was concluded that the adverse 
results of SEAS trial were due to chance.98 Similar conclu-
sions were reached from postmarketing analysis.99
Cost-effectiveness
No data have been published for cost-effectiveness of 
ezetimibe in FH patients. In the NICE guidance, several other 
clinical scenarios were discussed, and models were analyzed.7 
It was suggested that ezetimibe coadministered with a statin 
should not be recommended as an alternative to dose titration 
of the initiated statin where dose titration is possible and not 
prevented by the emergence of adverse effects.
The NICE Committee agreed that in non-FH patients, 
adding ezetimibe to initial statin therapy as a treatment option 
is a cost-effective use of National Health Service resources 
when compared with switching to an alternative statin.7 
Ezetimibe therapy in FH subjects is likely to be more cost-
effective because of the higher CVD risk of FH compared 
with non-FH populations.
Summary and recommendations
Physicians using ezetimibe should be familiar with the 
product information and refer to it for specific details of drug 
interaction, tolerability, and other details.1
Ezetimibe, a cholesterol absorption inhibitor, is indicated 
for the treatment of HC due to elevation of LDL-C. The 
rationale for its use in the treatment of HC is that it provides 
10%–20% further reduction in LDL-C levels compared 
with that achieved with a given dose of statin or any other 
  LDL-C-lowering therapy. Slightly higher percentage reduc-
tions are achieved with ezetimibe monotherapy compared 
with combination statin–ezetimibe therapy (see Figure 1). On 
the basis of many LDL-C-lowering trials, epidemiological 
studies, and animal experiments, there is a strong positive 
correlation between LDL-C levels, atherosclerosis severity, 
and incidence of atherothrombotic CVD. A reduction of 
LDL-C of 20% equates to a similar reduction in CVD events 
over a 5-year period. This has yet to be confirmed in a long-
term randomized controlled intervention trial with ezetimibe, 
although such a trial is expected to be completed in 2013. 
Until then, most authorities and lipidologists recommend the 
use of ezetimibe to further lower LDL-C in patients whose 
LDL-C is not at target despite other LDL-C-lowering therapy, 
or in patients intolerant of such therapies.
FH is a monogenic, autosomal dominant disorder caused 
by a mutation in the gene coding for the LDL-R. In heFH, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the presence of one abnormal LDL-R allele is associated 
with approximately 50% loss of LDL-R activity and 
two fold increase in plasma levels of LDL-C. This leads to 
accelerated atherosclerosis and premature CVD in the aged 
(50% of men with heFH have CVD by the age of 50 years 
and 50% of women by the age of 60–65 years). Young men 
with heFH have about 80 times higher standardized mortal-
ity rate than the general population. In hoFH patients, the 
presence of two abnormal LDL-R alleles is associated with 
approximately 100% loss of LDL-R activity and several-fold 
increases in plasma levels of LDL-C. This leads to markedly 
accelerated atherosclerosis and premature CVD often in the 
teenage years (some children suffer from CVD before the 
age of 10 years).
The prevalence of hoFH is about 1 per million of the 
population (but slightly higher in populations with increased 
LDL-R mutation gene frequency), and often results from 
consanguinity. The prevalence of heFH is about 1 per 500 of 
the population (up to 1:60–1:80 in populations with increased 
LDL-R mutation gene frequency such as French Canadians, 
Southern Afrikaners, and Lebanese). A survival value for the 
presence of LDL-R mutations has yet to be ascertained.
FH is recognized clinically by the combination of high 
LDL-C level, positive family history of premature CVD on 
one side of the family (males and females being equally 
affected, although clinical CVD usually occurs 10–15 years 
later in females), and clinical signs of LDL-C deposition. 
These include premature arcus senilis, xanthelasmas, and 
tendon and cutaneous xanthomas.
FH can be diagnosed at virtually any age, although 
sensitivity and specificity of LDL-C are lower in young 
children and older adults, when genetic testing may be more 
appropriate. Universal screening of children and adolescents 
(9–16 years) may be more cost-effective than cascade family 
screening, and it has been proposed that such screening takes 
place at the time of immunization.100 Use of the cutoff levels 
for median of the means of either TC or LDL-C levels may 
be more sensitive and specific than either lipid level alone.100 
Universal screening of children also has the potential for 
diagnosis of the affected parent and for improved efficiency 
of detection.100
The generally accepted paradigm for treatment of FH is 
as follows: the earlier the treatment and lower the LDL-C the 
better.101 Ideally, diagnosis is made in childhood, and statin 
therapy begun early. In adulthood, maximum doses of potent 
statins (atorvastatin 80 mg/d or rosuvastatin 40 mg/d) are 
used in combination with ezetimibe 10 mg/d. If necessary, 
additional measures to lower LDL-C are also used (NA, bile 
acid sequesterants, and/or fenofibrate therapy). At all ages, 
lifestyle measures are important, particularly avoidance of 
cigarette smoking. Dietary compliance can improve LDL-C 
control, as can weight control.
Some patients with ‘resistant’ heFH or hoFH require 
additional invasive measures to control LDL-C levels. If 
available, LDL-apheresis is highly effective but costly. An 
alternative is plasmapheresis, both requiring twice-weekly 
treatment sessions. For hoFH, apheresis may be bridging 
therapy for liver transplantation, the only proven effective 
long-term therapy for this condition. Previous treatment 
with attempted transfer of normal liver cells containing 
normal LDL-R alleles was unsuccessful. ApoB RNA-
silencing therapy is currently under trial with the novel 
drug, mipomersin, which in Phase II studies lowered LDL-C 
levels by a somewhat disappointing ∼20% and increased 
liver transaminases.102
Regression of atherosclerosis and reduction in CVD 
events have been observed in short-term studies of FH 
patients with LDL-C-lowering therapy. However, no 
long-term RCTs have been performed in which aggres-
sive LDL-C lowering with high-dose statin therapy plus 
ezetimibe or NA has been compared with other therapy in 
patients with FH.
The efficacy of treating patients with heFH in the 
“real world” was recently determined in the Netherlands, 
a country renowned for the quality of its cascade family 
screening program for FH, as well as for the high quality 
of its medical care.103,104 European and Dutch guidelines 
currently recommend treatment for lowering LDL-C in 
heFH patients to plasma levels ,2.5 mmol/l.92 A cross-
sectional study of 5 outpatient lipid clinics included 1,249 
patients with heFH; 96% of patients were on statin treat-
ment. The LDL-C goal ,2.5 mmol/L was achieved in only 
21% of patients. Of those not reaching LDL-C goals, 27% 
were on maximum statin dose and ezetimibe, and in 32%, 
acceptance of a higher target LDL-C level by the treating 
physician was the main reason for goal achievement fail-
ure. An alternative treatment goal of .50% reduction in 
LDL-C levels, as recommended in the NICE guidelines, 
was achieved in 47% of patients who had LDL-C lev-
els $2.5 mmol/L and were not using maximum therapy.103 
These data suggest the necessity for greater education of 
physicians on the need to achieve LDL-C goals in heFH 
patients.
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